Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Paxlovid study #1   All Outcomes
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mortality 95% Imp. Relative Risk, 95% CI Mortality (b) 93% Hospitalization 85% Hospitalization (b) 89% Pfizer: Pfizer's novel COVID-19 oral antiviral treatment candida.. c19early.com/pfizerpaxlovid.html Favors paxlovid Favors control
11/5 Early treatment study
Pfizer Press Release (News)
Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study
Source   PDF   Share   Tweet
Interim analysis of EPIC-HR, 607 higher risk patients treated with paxlovid (PF-07321332 + ritonavir) and 612 control patients, showing significantly lower mortality and hospitalization with treatment.
risk of death, 95.2% lower, RR 0.05, p = 0.002, treatment 0 of 607 (0.0%), control 10 of 612 (1.6%), relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), within 5 days.
risk of death, 93.4% lower, RR 0.07, p = 0.007, treatment 0 of 389 (0.0%), control 7 of 385 (1.8%), relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), within 3 days.
risk of hospitalization, 85.2% lower, RR 0.15, p < 0.001, treatment 6 of 607 (1.0%), control 41 of 612 (6.7%), within 5 days.
risk of hospitalization, 89.0% lower, RR 0.11, p < 0.001, treatment 3 of 389 (0.8%), control 27 of 385 (7.0%), within 3 days.
Pfizer et al., 11/5/2021, Double Blind Randomized Controlled Trial, multiple countries, multiple regions, preprint, 1 author.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical significance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
All Studies   All Outcomes
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Submit